Skip to main content
SpringerLink
Log in

Coupling Apoptosis and Cell Division Control in Cancer

The Survivin Paradigm

  • Chapter
Apoptosis, Cell Signaling, and Human Diseases

  • 904 Accesses

Summary

The interface between cell proliferation and cell death is thought to function as a pivotal crossroad essential to the preservation of normal homeostasis and to eliminate dangerous cells before they divide. Survivin is a prototype molecule at this crossroad, intercalated in protection against mitochondrial cell death and orchestrating various aspects of cell division. Dramatically exploited in cancer and an unfavorable gene signature for disease outcome, the survivin pathway provides tangible opportunities for targeted, rational cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239–257.

    PubMed  CAS  Google Scholar 

  2. Meier P, Finch A, Evan GI. Apoptosis in development. Nature 2000;407:796–801.

    Article  PubMed  CAS  Google Scholar 

  3. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770–776.

    Article  PubMed  CAS  Google Scholar 

  4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.

    Article  PubMed  CAS  Google Scholar 

  5. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647–656.

    Article  PubMed  CAS  Google Scholar 

  6. Salvesen GS, Duckett CS. Apoptosis: IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol 2002;3:401–410.

    Article  PubMed  CAS  Google Scholar 

  7. Yoo SJ, Huh JR, Muro I, et al. Hid, Rpr and Grim negatively regulate DIAP1 levels through distinct mechanisms. Nat Cell Biol 2002;4:416–424.

    Article  PubMed  CAS  Google Scholar 

  8. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917–921.

    Article  PubMed  CAS  Google Scholar 

  9. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000;7: 602–608.

    Article  PubMed  CAS  Google Scholar 

  10. Chantalat L, Skoufias D, Kleman JP, Jung B, Dideberg O, Margolis RL. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell 2000;6:183–189.

    Article  PubMed  CAS  Google Scholar 

  11. Muchmore SW, Chen J, Jakob C, et al. Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell 2000;6:173–182.

    Article  PubMed  CAS  Google Scholar 

  12. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580–584.

    Article  PubMed  CAS  Google Scholar 

  13. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999;59:3143–3151.

    PubMed  CAS  Google Scholar 

  14. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999;59:6097–6102.

    PubMed  CAS  Google Scholar 

  15. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005;4:11.

    Article  PubMed  CAS  Google Scholar 

  16. Mahotka C, Liebmann J, Wenzel M, et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 2002;9:1334–1342.

    Article  PubMed  CAS  Google Scholar 

  17. Kobayashi K, Hatano M, Otaki M, Ogasawara T, Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci USA 1999;96:1457–1462.

    Article  PubMed  CAS  Google Scholar 

  18. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem. J. 344 Pt 1999;2:305–311.

    Google Scholar 

  19. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell Sci. 113 Pt 2000; 23:4363–4371.

    Google Scholar 

  20. O’Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002;2:43–54.

    Article  PubMed  CAS  Google Scholar 

  21. Fukuda S, Foster RG, Porter SB, Pelus LM. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 2002;100:2463–2471.

    Article  PubMed  CAS  Google Scholar 

  22. Papapetropoulos A, Fulton D, Mahboubi K, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000;275:9102–9105.

    Article  PubMed  CAS  Google Scholar 

  23. Harfouche R, Hassessian HM, Guo Y, et al. Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 2002;64:135–147.

    Article  PubMed  CAS  Google Scholar 

  24. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905–2927.

    Article  PubMed  CAS  Google Scholar 

  25. Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001;97:2784–2790.

    Article  PubMed  CAS  Google Scholar 

  26. Fornaro M, Plescia J, Chheang S, et al. Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor-a-induced Apoptosis via the AKT/Survivin Pathway. J Biol Chem 2003;278:50,402–50,411.

    Article  PubMed  CAS  Google Scholar 

  27. Mahboubi K, Li F, Plescia J, et al. Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab Invest 2001;81:327–334.

    PubMed  CAS  Google Scholar 

  28. Iurlaro M, Demontis F, Corada M, et al. VE-Cadherin Expression and Clustering Maintain Low Levels of Survivin in Endothelial Cells. Am J Pathol 2004;165:181–189.

    PubMed  CAS  Google Scholar 

  29. Ohashi H, Takagi H, Oh H, et al. Phosphatidylinositol 3-Kinase/Akt Regulates Angiotensin II-Induced Inhibition of Apoptosis in Microvascular Endothelial Cells by Governing Survivin Expression and Suppression of Caspase-3 Activity. Circ Res 2004;94:785–793.

    Article  PubMed  CAS  Google Scholar 

  30. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101:1535–1542.

    Article  PubMed  CAS  Google Scholar 

  31. Shen Y, Devgan G, Darnell JE, Jr,Bromberg JF. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA 2001;98:1543–1548.

    Article  PubMed  CAS  Google Scholar 

  32. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613–6626.

    Article  PubMed  CAS  Google Scholar 

  33. Li F, Ackermann EJ, Bennett CF, Rothermel AL, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999;1:461–466.

    Article  PubMed  CAS  Google Scholar 

  34. Jiang X, Wilford C, Duensing S, Munger K, Jones G, Jones D. Participation of Survivin in mitotic and apoptotic activities of normal and tumor-derived cells. J Cell Biochem 2001;83:342–354.

    Article  PubMed  CAS  Google Scholar 

  35. Skoufias DA, Mollinari C, Lacroix FB, Margolis RL. Human survivin is a kinetochoreassociated passenger protein. J Cell Biol2000;151:1575–1582.

    Article  PubMed  CAS  Google Scholar 

  36. Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002;115: 575–585.

    PubMed  CAS  Google Scholar 

  37. Wheatley SP, Carvalho A, Vagnarelli P, Earnshaw WC. INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol 2001;11:886–890.

    Article  PubMed  CAS  Google Scholar 

  38. Rodriguez JA, Span SW, Ferreira CG, Kruyt FA, Giaccone G. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res 2002;275:44–53.

    Article  PubMed  CAS  Google Scholar 

  39. Wheatley SP, Henzing AJ, Dodson H, Khaled W, Earnshaw WC. Aurora-B Phosphorylation in Vitro Identifies a Residue of Survivin That Is Essential for Its Localization and Binding to Inner Centromere Protein (INCENP) in Vivo. J Biol Chem 2004;279:5655–5660.

    Article  PubMed  CAS  Google Scholar 

  40. Uren AG, Beilharz T, O’Connell MJ, et al. Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division. Proc Natl Acad Sci USA 1999;96:10,170–10,175.

    Article  PubMed  CAS  Google Scholar 

  41. Fraser AG, James C, Evan GI, Hengartner MO. Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. Curr Biol 1999;9:292–301.

    Article  PubMed  CAS  Google Scholar 

  42. Uren AG, Wong L, Pakusch M, et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000;10: 1319–1328.

    Article  PubMed  CAS  Google Scholar 

  43. Conway EM, Pollefeyt S, Steiner-Mosonyi M, et al. Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology 2002;123:619–631.

    Article  PubMed  CAS  Google Scholar 

  44. Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 2001;11:49–54.

    Article  PubMed  CAS  Google Scholar 

  45. Speliotes EK, Uren A, Vaux D, Horvitz HR. The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. Mol. Cell 2000;6:211–223.

    Article  PubMed  CAS  Google Scholar 

  46. Chen J, Jin S, Tahir SK, et al. Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells. J Biol Chem 2003;278:486–490.

    Article  PubMed  CAS  Google Scholar 

  47. Bolton MA, Lan W, Powers SE, et al. Aurora B Kinase Exists in a Complex with Survivin and INCENP and Its Kinase Activity Is Stimulated by Survivin Binding and Phosphorylation. Mol Biol Cell 2002;13:3064–3077.

    Article  PubMed  CAS  Google Scholar 

  48. Kallio MJ, Nieminen M, Eriksson JE. Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. Faseb J 2001;15:2721–2723.

    PubMed  CAS  Google Scholar 

  49. Giodini A, Kallio M, Wall NR, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002;62:2462–2467.

    PubMed  CAS  Google Scholar 

  50. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, and Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002;99: 4349–4354.

    Article  PubMed  CAS  Google Scholar 

  51. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA 2004;101:15,100–15,105.

    Article  PubMed  CAS  Google Scholar 

  52. Lens SM, Wolthuis RM, Klompmaker R, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. Embo J 2003;22:2934–2947.

    Article  PubMed  CAS  Google Scholar 

  53. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003;116:2987–2998.

    Article  PubMed  CAS  Google Scholar 

  54. Beltrami E, Plescia J, Wilkinson JC, Duckett CS, Altieri DC. Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem 2004;279:2077–2084.

    Article  PubMed  CAS  Google Scholar 

  55. Gassmann R, Carvalho A, Henzing AJ, et al. Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J Cell Biol 2004;166:179–191.

    Article  PubMed  CAS  Google Scholar 

  56. Sampath SC, Ohi R, Leismann O, Salic A, Pozniakovski A, Funabiki H. The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly. Cell 2004;118:187–202.

    Article  PubMed  CAS  Google Scholar 

  57. Altieri DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003;5:447–452.

    PubMed  Google Scholar 

  58. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004;23:2825–2837.

    Article  PubMed  CAS  Google Scholar 

  59. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005;92: 212–216.

    PubMed  CAS  Google Scholar 

  60. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592–603.

    Article  PubMed  CAS  Google Scholar 

  61. Grossman D, Kim PJ, Blanc-Brude OP, et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 2001;108:991–999.

    Article  PubMed  CAS  Google Scholar 

  62. Jones G, Jones D, Zhou L, Steller H, Chu Y. Deterin, a new inhibitor of apoptosis from Drosophila melanogaster. J. Biol. Chem. 2000;275:22,157–22,165.

    Article  PubMed  CAS  Google Scholar 

  63. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315–5320.

    PubMed  CAS  Google Scholar 

  64. Kasof GM, Gomes BC. Livin, a novel inhibitor-of-apoptosis (IAP) family member. J. Biol. Chem. 2000;276:3238–3246.

    Article  PubMed  Google Scholar 

  65. Conway EM, Pollefeyt S, Cornelissen J, et al. Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 2000;95: 1435–1442.

    PubMed  CAS  Google Scholar 

  66. Shin S, Sung, BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7. Biochemistry 2001;40:1117–1123.

    Article  PubMed  CAS  Google Scholar 

  67. Banks DP, Plescia J, Altieri DC, et al. Survivin does not inhibit caspase-3 activity. Blood 2000;96:4002–4003.

    PubMed  CAS  Google Scholar 

  68. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002; 9:459–470.

    Article  PubMed  CAS  Google Scholar 

  69. O’Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. USA 2000;97:13,103–13,107.

    Article  PubMed  CAS  Google Scholar 

  70. McNeish IA, Lopes R, Bell SJ, et al. Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp Cell Res 2005;302:69–82.

    Article  PubMed  CAS  Google Scholar 

  71. Song Z, Liu S, He H, et al. A Single Amino Acid Change (Asp 53->Ala53) Converts Survivin from anti-apoptotic to pro-apoptotic. Mol Biol Cell 2004;15:1287–1296.

    Article  PubMed  CAS  Google Scholar 

  72. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003;278:23,130–23,140.

    Article  PubMed  CAS  Google Scholar 

  73. Sun C, Nettesheim D, Liu Z, Olejniczak ET. Solution structure of human survivin and its binding interface with Smac/Diablo. Biochemistry 2005;44:11–17.

    Article  PubMed  CAS  Google Scholar 

  74. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001;108:981–990.

    Article  PubMed  CAS  Google Scholar 

  75. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15: 2922–2933.

    PubMed  CAS  Google Scholar 

  76. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33–42.

    Article  PubMed  CAS  Google Scholar 

  77. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004;114:1117–1127.

    Article  PubMed  CAS  Google Scholar 

  78. Dohi T, Altieri DC. Mitochondrial dynamics of survivin and “four dimensional” control of tumor cell apoptosis. Cell Cycle 2005;4:21–23.

    PubMed  CAS  Google Scholar 

  79. Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. Embo J 2003;22:2729–2740.

    Article  PubMed  CAS  Google Scholar 

  80. Dohi T, Okada K, Xia F, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004;279:34,087–34,090.

    Article  PubMed  CAS  Google Scholar 

  81. Wang HW, Sharp TV, Koumi A, Koentges G, and Boshoff C. Characterization of an antiapoptotic glycoprotein encoded by Kaposi’s sarcoma-associated herpesvirus which resembles a spliced variant of human survivin. Embo J 2002;21:2602–2615.

    Article  PubMed  CAS  Google Scholar 

  82. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998;152:43–49.

    PubMed  CAS  Google Scholar 

  83. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3: 46–54.

    Article  PubMed  CAS  Google Scholar 

  84. Bao R, Connolly DC, Murphy M, et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2002;94:522–528.

    PubMed  CAS  Google Scholar 

  85. O’Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000;156:393–398.

    PubMed  CAS  Google Scholar 

  86. Tran J, Rak J, Sheehan C, et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res Commun 1999;264:781–788.

    Article  PubMed  CAS  Google Scholar 

  87. Dan HC, Jiang K, Coppola D, et al. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 2004;23:706–715.

    Article  PubMed  CAS  Google Scholar 

  88. Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S, Cerni C. Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene 2003;22: 4266–4280.

    Article  PubMed  CAS  Google Scholar 

  89. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247–3257.

    Article  PubMed  CAS  Google Scholar 

  90. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002;21:2613–2622.

    Article  PubMed  CAS  Google Scholar 

  91. Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ, Boman BM. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001;61:8664–8667.

    PubMed  CAS  Google Scholar 

  92. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003;362:205–209.

    Article  PubMed  CAS  Google Scholar 

  93. Xu ZX, Zhao RX, Ding T, et al. Promyelocytic leukemia protein 4 induces apoptosis by inhibition of survivin expression. J Biol Chem 2004;279:1838–1844.

    Article  PubMed  CAS  Google Scholar 

  94. van Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–536.

    Article  Google Scholar 

  95. Kuttler F, Valnet-Rabier MB, Angonin R, et al. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 2002;16:726–735.

    Article  PubMed  CAS  Google Scholar 

  96. van de Wetering M, Sancho E, Vervweij C, et al. The b-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002;111:241–250.

    Article  PubMed  Google Scholar 

  97. Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003;9:931–946.

    PubMed  CAS  Google Scholar 

  98. Paik S, Shak S, Tang G. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–2826.

    Article  PubMed  CAS  Google Scholar 

  99. Andersen MH, Thor SP. Survivin-a universal tumor antigen. Histol Histopathol 2002;17: 669–675.

    PubMed  CAS  Google Scholar 

  100. Rohayem J, Diestelkoetter P, Weigle B, et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000;60: 1815–1817.

    PubMed  CAS  Google Scholar 

  101. Yagihashi A, Asanuma K, Nakamura M, et al. Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin Chem 2001;47:1729–1731.

    PubMed  CAS  Google Scholar 

  102. Schmitz M, Diestelkoetter P, Weigle B, et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000;60: 4845–4849.

    PubMed  CAS  Google Scholar 

  103. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001;61:869–872.

    PubMed  CAS  Google Scholar 

  104. Hirohashi Y, Torigoe T, Maeda A, et al. An HLA-A24-restricted Cytotoxic T Lymphocyte Epitope of a Tumor-associated Protein, Survivin. Clin Cancer Res 2002;8:1731–1739.

    PubMed  CAS  Google Scholar 

  105. Schmidt SM, Schag K, Muller MR, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003;102:571–576.

    Article  PubMed  CAS  Google Scholar 

  106. Idenoue S, Hirohashi Y, Torigoe T, et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 2005;11:1474–1482.

    Article  PubMed  CAS  Google Scholar 

  107. Casati C, Dalerba P, Rivoltini L, et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 2003;63: 4507–4515.

    PubMed  CAS  Google Scholar 

  108. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI. Full-Length Dominant-Negative Survivin for Cancer Immunotherapy. Clin Cancer Res 2003;9:6523–6533.

    PubMed  CAS  Google Scholar 

  109. Siegel S, Wagner A, Schmitz N, Zeis M. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 2003;122: 911–914.

    Article  PubMed  Google Scholar 

  110. Xiang R, Mizutani N, Luo Y., Chiodoni C, et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 2005;65:553–561.

    PubMed  CAS  Google Scholar 

  111. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004;22:2808–2815.

    Article  PubMed  Google Scholar 

  112. Otto K, Andersen MH, Eggert A, et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005;23:884–889.

    Article  PubMed  CAS  Google Scholar 

  113. Tsuruma T, Hata F, Torigoe T, et al. Phase I clinical study of anti-apoptosis protein, survivinderived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004;2:19.

    Article  PubMed  CAS  Google Scholar 

  114. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and b7-1 immunogene therapy. J Natl Cancer Inst 2001; 93:1541–1552.

    Article  PubMed  CAS  Google Scholar 

  115. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. USA 2001;98:635–640.

    Article  PubMed  CAS  Google Scholar 

  116. Yamamoto T, Manome Y, Nakamura M, Tanigawa N. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 2002;38:2316–2324.

    Article  PubMed  CAS  Google Scholar 

  117. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003;9:2683–2692.

    PubMed  CAS  Google Scholar 

  118. Pennati M, Binda M, Colella G, et al. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 2004;23:386–394.

    Article  PubMed  CAS  Google Scholar 

  119. Ansell SM, Arendt BK, Grote DM, et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin’s lymphoma. Leukemia 2004;18:616–623.

    Article  PubMed  CAS  Google Scholar 

  120. Wall NR, O’Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 62003;3:230–235.

    Google Scholar 

  121. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003;100:13,791–13,796.

    Article  PubMed  CAS  Google Scholar 

  122. Nollen EAA, Morimoto RI. Chaperoning signaling pathways: molecular chaperones as stress-sensing “heat shock” proteins. J Cell Sci 2002;115:2809–2816.

    PubMed  CAS  Google Scholar 

  123. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8:S55–S61.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA

    Dario C. Altieri

Authors
  1. Dario C. Altieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biochemistry, University of Texas Health Center at Tyler, Tyler, TX

    Rakesh Srivastava

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Altieri, D.C. (2007). Coupling Apoptosis and Cell Division Control in Cancer. In: Srivastava, R. (eds) Apoptosis, Cell Signaling, and Human Diseases. Humana Press. https://doi.org/10.1007/978-1-59745-200-7_14

Download citation

Publish with us

Policies and ethics

Search

Navigation